Ghrelin Peptide Protects Heart from Thyroid Hormone Damage in Rats
Background
High levels of thyroid hormones, as seen in conditions like hyperthyroidism, can lead to severe cardiac damage, characterized by oxidative stress, inflammation, and dysfunction of the renin-angiotensin system. Current therapeutic strategies often have limitations or side effects. This study aimed to investigate if acylated ghrelin could mitigate l-thyroxin-induced cardiac damage in a rat model.
Results
Acylated ghrelin treatment significantly improved cardiac function and attenuated l-thyroxin-induced damage. The most important finding was a 45% reduction in myocardial fibrosis and a 30% improvement in left ventricular ejection fraction in ghrelin-treated rats compared to the l-thyroxin-only group (p<0.001). Oxidative stress was markedly reduced, with malondialdehyde (MDA) levels decreasing by 35% (p<0.01) and antioxidant enzyme activity, such as superoxide dismutase (SOD), increasing by 2.2-fold (p<0.001). Furthermore, inflammatory cytokines including TNF-α and IL-6 were reduced by 40% and 38% respectively (p<0.05). Crucially, key components of the cardiac renin-angiotensin system, such as ACE and AT1R, were downregulated by 50% and 48% (p<0.001), indicating a multi-target protective mechanism.
Why It Matters
This research highlights acylated ghrelin's significant potential as a therapeutic agent for mitigating cardiac damage caused by excessive thyroid hormones. Its ability to simultaneously combat oxidative stress, reduce inflammation, and modulate the renin-angiotensin system suggests a comprehensive cardioprotective effect. These findings could lead to the development of novel pharmacological strategies for preventing or treating hyperthyroidism-related heart complications. Future steps should involve further mechanistic studies and eventually human clinical trials to confirm these promising results.